Merck CEO will take charge of the company’s chairman
On Wednesday, the company Merck & Co announced that Ken Frazier leaves the post of chairman. He will be replaced by Chief Executive Officer Rob Davis, who has taken on extra responsibilities on December 1.
Frazier joined the company nearly 30 years ago, and over the years, he was helping the company to stay among the leaders in the drug production field.
He was steering the company during the difficult lawsuit related to the painkiller Vioxx, which was withdrawn from the market. He also played a pivotal role in the acquisition of US drug product manufacturer Schering-Plough. In 2009 the company received the possibility to sell the drug Keytruda. Then, this drug became Merck's best-selling product.
Recommended
Energy and Precious Metals Market events for February 2-3, 2023
2 February 2023
Last year recorded an increased demand for gold up to the levels of 2011
1 February 2023
Exxon Mobile is criticized for $56 billion profit
1 February 2023
White House Supports Alaska Oil Project
1 February 2023
Aluminum buyers from Japan agreed to pay extra charges in the first quarter
1 February 2023
Top news
Nothing found